Low plasma zinc levels and immunological responses to zinc supplementation in HIV-infected patients with immunological discordance after antiretroviral therapy

Japanese Journal of Infectious Diseases

Volumn 66, Issue 6, 2013, Pages 469-474

  Asdamongkol, Nakhon ^a   Phanachet, Pariya ^b   Sungkanuparph, Somnuek ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; CD4+; HIV; Immunological discordance; Zinc

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; PLACEBO; STAVUDINE; TENOFOVIR; VIRUS DNA; ZIDOVUDINE; ZINC;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOLOGICAL DISCORDANCE; MALE; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ZINC BLOOD LEVEL;

ADULT; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; ZINC;

EID: 84888108616     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.66.469     Document Type: Article

References (36)

1. Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., et al. (1998): Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med., 338, 853-860.
2. Manosuthi, W., Chottanapand, S., Thongyen, S., et al. (2006): Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J. Acquired Immune Defic. Syndr., 43, 42-46.
3. Sungkanuparph, S., Chakriyanuyok, T. and Butthum, B. (2008): Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome. J. Infect., 56, 40-43.
4. Jongwutiwes, U., Kiertiburanakul, S. and Sungkanuparph, S. (2007): Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr. HIV Res., 5, 355-360.
5. Raboud, J.M., Rae, S., Hogg, R.S., et al. (1999): Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. J. Infect. Dis., 180, 1347-1350.
6. Sungkanuparph, S., Techasathit, W., Utaipiboon, C., et al. (2010): Thai national guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2010. Asian Biomed., 4, 515-528.
7. Kaufmann, G.R., Perrin, L., Pantaleo, G., et al. (2003): CD4 Tlymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch. Intern. Med., 163, 2187-2195.
8. Sungkanuparph, S., Anekthananon, T., Hiransuthikul, N., et al. (2008): Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J. Med. Assoc. Thai., 91, 1925-1935.
9. Mellors, J.W., Munoz, A., Giorgi, J.V., et al. (1997): Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med., 126, 946-954.
10. Moore, R.D. and Chaisson, R.E. (1996): Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann. Intern. Med., 124, 633-642.
11. Kaplan, J.E., Benson, C., Holmes, K.H., et al. (2009): Guidelines for prevention and treatment of opportunistic infections in HIVinfected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Morbid. Mortal. Wkly. Rep., 58 (RR-4), 1-207.
12. Hammer, S.M. (2005): Clinical practice. Management of newly diagnosed HIV infection. N. Engl. J. Med., 353, 1702-1710.
13. Moore, D.M., Hogg, R.S., Yip, B., et al. (2005): Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J. Acquired Immune Defic. Syndr., 40, 288-293.
14. Grabar, S., LeMoing, V., Goujard, C., et al. (2000): Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med., 133, 401-410.
15. Gazzola, L., Tincati, C., Bellistri, G.M., et al. (2009): The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin. Infect. Dis., 48, 328-337.
16. Kaufmann, G.R., Bloch, M., Finlayson, R., et al. (2002): The extent of HIV-1-related immunodeficiency and age predict the longterm CD4 T lymphocyte response to potent antiretroviral therapy. AIDS, 16, 359-367.
17. Dronda, F., Moreno, S., Moreno, A., et al. (2002): Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression. Clin. Infect. Dis., 35, 1005-1009.
18. o500 cells/mL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis., 41, 361-372.
19. Crespo, M., Caragol, I., Falco, V., et al. (2008): Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART. Enferm. Infecc. Microbiol. Clin., 26, 27-31.
20. Abrams, D., Levy, Y., Losso, M.H., et al. (2009): Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med., 361, 1548-1559.
21. Panel on Antiretroviral Guidelines for Adults and Adolescents (2012): Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Online at . Accessed on 24 May 2012.
22. Baum, M.K., Lai, S., Sales, S., et al. (2010): Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults. Clin. Infect. Dis., 50, 1653-1660.
23. Mehta, S. and Fawzi, W.W. (2010): Micronutrient supplementation as adjunct treatment for HIV-infected patients. Clin. Infect. Dis., 50, 1661-1663.
24. Jones, C.Y., Tang, A.M., Forrester, J.E., et al. (2006): Micronutrient levels and HIV disease status in HIV-infected patients on highly active antiretroviral therapy in the nutrition for healthy living cohort. J. Acquired Immune Defic. Syndr., 43, 475-482.
25. Baum, M.K., Shor-Posner, G. and Campa, A. (2000): Zinc status in human immunodeficiency virus infection. J. Nutr., 130 (5S Suppl), 1421S-1423S.
26. Graham, N.M., Sorensen, D., Odaka, N., et al. (1991): Relationship of serum copper and zinc levels to HIV-1 seropositivity and progression to AIDS. J. Acquired Immune Defic. Syndr., 4, 976-980.
27. Ferencik, M. and Ebringer, L. (2003): Modulatory effects of selenium and zinc on the immune system. Folia Microbiol. (Praha), 48, 417-426.
28. Baum, M.K., Shor-Posner, G., Lu, Y., et al. (1995): Micronutrients and HIV-1 disease progression. AIDS, 9, 1051-1056.
29. Mocchegiani, E., Veccia, S., Ancarani, F., et al. (1995): Benefit of oral zinc supplementation as an adjunct to zidovudine (AZT) therapy against opportunistic infections in AIDS. Int. J. Immunopharmacol., 17, 719-727.
30. Baum, M.K., Campa, A., Lai, S., et al. (2003): Zinc status in human immunodeficiency virus type 1 infection and illicit drug use. Clin. Infect. Dis., 37 (Suppl 2), S117-S123.
31. Kupka, R. and Fawzi, W. (2002): Zinc nutrition and HIV infection. Nutr. Rev., 60, 69-79.
32. Khalili, H., Soudbakhsh, A., Hajiabdolbaghi, M., et al. (2008): Nutritional status and serum zinc and selenium levels in Iranian HIV infected individuals. BMC Infect. Dis., 8, 165.
33. Roungsipragarn, R., Borirug, S. and Herabutya, Y. (1999): Plasma zinc level and intrauterine growth retardation: a study in pregnant women in Ramathibodi Hospital. J. Med. Assoc. Thai., 82, 178-181.
34. Lowe, N.M., Medina, M.W., Stammers, A.L., et al. (2012): The relationship between zinc intake and serum/plasma zinc concentration in adults: a systematic review and dose-response metaanalysis by the EURRECA Network. Br. J. Nutr., 108, 1962-1971.
35. Foster, D.M., Aamodt, R.L., Henkin, R.I., et al. (1979): Zinc metabolism in humans: a kinetic model. Am. J. Physiol., 237, R340-R349.
36. King, J.C., Shames, D.M. and Woodhouse, L.R. (2000): Zinc homeostasis in humans. J. Nutr., 130, 1360S-1366S.